NCT00560820已完成1 期
Phase I Study to Examine the Effect of Deferasirox on Renal Hemodynamics in β-thalassemia Patients With Transfusional Iron Overload
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 11
- 试验地点
- 1
- 主要终点
- Effect of deferasirox on renal hemodynamics in patients with β-thalassemia and transfusional iron overload.
研究概览
简要总结
The primary purpose of this study is to evaluate the effect of deferasirox on renal hemodynamics by determining glomerular filtration rate (GFR), renal plasma flow (RPF) and filtration fraction (FF).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究组 & 干预措施
Deferasirox
Experimental
30 mg/kg/day
干预措施: Deferasirox (Drug)
结局指标
主要结局
Effect of deferasirox on renal hemodynamics in patients with β-thalassemia and transfusional iron overload.
时间窗: Once a month
次要结局
- Effect of deferasirox on standard markers of renal function(Once a month)
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
不适用
Phase I study to examine the effect of deferasirox on renal hemodynamics in β-thalassemia patients with transfusional iron overload - NDMedDRA version: 6.1Level: HLGTClassification code 10022958thalassemiaEUCTR2006-006838-17-ITOVARTIS FARMA8
终止
2 期
A Phase II Pilot Study to Assess the Presence of Molecular Factors Predictive for Hematologic Response in Myelodysplastic Syndrome Patients Receiving Deferasirox Therapy.Myelodysplastic SyndromeNCT02663752Novartis Pharmaceuticals1
已完成
2 期
Study of Deferasirox in Iron Overload From Beta-thalassemia Unable to be Treated With Deferoxamine or Chronic AnemiasBeta-thalassemiaMyelodysplastic SyndromesFanconi SyndromeAnemia, Diamond-BlackfanAnemia, AplasticNCT00061763Novartis Pharmaceuticals175
已完成
2 期
Combination Study of Deferasirox and Erythropoietin in Patients With Low- and Int-1-risk Myelodysplastic Syndrome.Low and Int 1-risk Myelodysplastic SyndromeNCT01868477Novartis Pharmaceuticals28
已完成
1 期
Study to Investigate the Effect of Deferasirox on the Pharmacokinetics of MidazolamHealthyNCT00427505Novartis22